Octreotide long-term treatment in patients with portal hypertension: persistent inhibition of postprandial glucagon response without major changes in renal function (Q51576045)

From Wikidata

Jump to navigation Jump to search

scientific article published in April 1997

Language	Label	Description	Also known as
English	Octreotide long-term treatment in patients with portal hypertension: persistent inhibition of postprandial glucagon response without major changes in renal function	scientific article published in April 1997

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9126794

Octreotide long-term treatment in patients with portal hypertension: persistent inhibition of postprandial glucagon response without major changes in renal function (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9126794

1 reference

based on heuristic

inferred from title

portal hypertension

1 reference

based on heuristic

inferred from title

author name string

Malesci A

1

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9126794

Tacconi M

2

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9126794

Valentini A

3

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9126794

Basilico M

4

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9126794

Lorenzano E

5

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9126794

Salerno F

6

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9126794

publication date

1 April 1997

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9126794

Journal of Hepatology

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9126794

26

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9126794

4

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9126794

816-825

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9126794

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980247-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Review: long-acting somatostatin analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980247-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The influence of a long-acting somatostatin analogue on splanchnic haemodynamics and metabolism in healthy subjects and patients with liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980247-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Haemodynamic effects of a long-acting somatostatin analogue in patients with liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980247-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of a long-acting somatostatin analogue on portal and systemic haemodynamics in cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980247-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980247-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980247-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Postprandial hemodynamic responses in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980247-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Intestinal vascular sensitivity to vasopressin in portal hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980247-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980247-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Contractile and dilatory action of neuropeptides on isolated human mesenteric blood vessels

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980247-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Somatostatin does not Cause Sustained Fasting Hyperglycemia in Man

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980247-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhancement of renal function by a long-acting somatostatin analogue in patients with decompensated cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980247-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Octreotide ameliorates vasodilatation and Na+ retention in portal hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980247-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of somatostatin on kidney function and vasoactive hormone systems in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980247-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Antidiuretic effect of Sandostatin (SMS 201-995) in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980247-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Somatostatin inhibits the effect of secretin on bile flow and on hepatic bilirubin transport in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980247-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Octreotide decreased liver metabolic activity in patients with hepatitis B surface antigen-positive cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2897%2980247-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0168-8278(97)80247-4

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9126794

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9126794

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51576045&oldid=2277420004"